There are 2137 resources available
621P - Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A update
Presenter: Jose Arranz Arija
Session: E-Poster Display
Resources:
Abstract
622P - Exploring the impact of treatment switching on the interim overall survival (OS) results of the PROfound study
Presenter: Neeraj Agarwal
Session: E-Poster Display
Resources:
Abstract
623P - KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update
Presenter: Aurelius Omlin
Session: E-Poster Display
Resources:
Abstract
624P - Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound
Presenter: Guilhem Roubaud
Session: E-Poster Display
Resources:
Abstract
625P - Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update
Presenter: Loic Mourey
Session: E-Poster Display
Resources:
Abstract
626P - Cabazitaxel treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) in daily practice: Interim analysis of the non-interventional SCOPE study
Presenter: Carsten Bokemeyer
Session: E-Poster Display
Resources:
Abstract
627P - Real-world evidence (RWE) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ): Comparison with the randomized clinical study CARD
Presenter: Ronald de Wit
Session: E-Poster Display
Resources:
Abstract
628P - Treatment in CARD eligible metastatic castration resistant prostate cancer (mCRPC) patients according to the status of germline HRR mutations: Cabazitaxel (CBZ) vs enzalutamide/abiraterone
Presenter: Casilda Llacer Perez
Session: E-Poster Display
Resources:
Abstract
629P - Neutrophil-lymphocyte ratio (NLR) as a prognostic and predictive biomarker in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ) vs abiraterone or enzalutamide in the CARD study
Presenter: Ronald de Wit
Session: E-Poster Display
Resources:
Abstract
630P - Apalutamide for non-metastatic castration resistant prostate cancer (nmCRPC): A comparison of real-life experience from an international named patient program (NPP) vs the prior phase III clinical study
Presenter: Heather Payne
Session: E-Poster Display
Resources:
Abstract